Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Subscribe To Our Newsletter & Stay Updated
